Ongoing Memory Disorders Trials
The following studies are ongoing, but are not currently enrolling new participants.
The A4 Study
The purpose of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the "A4 Study" for short) is to test whether a new investigational treatment, called an anti-amyloid antibody, can slow memory loss caused by Alzheimer’s disease. Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits. Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss. The overall goal of the A4 Study is to test whether decreasing amyloid with an antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people.
This Phase 3 trial will test the effectiveness of the experimental drug BAN2401 as a possible treatment for Alzheimer's disease. BAN2401 is a monoclonal antibody that interferes with the formation of amyloid plaque, a hallmark of Alzheimer's. This 18-month study will test the effectiveness of the study drug in people with MCI or early Alzheimer's disease.
Embark is a study to evaluate the long-term safety and efficacy of Aducanumab in eligible participants with Alzheimer’s disease.
In Alzheimer’s disease, the brain develops abnormal clumps of protein called amyloid plaques. When these amyloid plaques build up, they can cause problems with memory and thinking. Scientists believe that the medicine being tested in this study, LY3002813, may help treat Alzheimer’s disease by removing amyloid plaques from the brain.